Drug General Information
Drug ID
D00GZY
Former ID
DNC014897
Drug Name
AT1001
Drug Type
Small molecular drug
Indication Autoimmune diabetes [ICD10:E08-E13] Phase 3 [522704]
Structure
Download
2D MOL

3D MOL

Formula
C34H59N9O12
Canonical SMILES
CC(C)CC(C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)N1CCCC1C(=O<br />)NCC(=O)O)NC(=O)C(C(C)C)NC(=O)CNC(=O)CN.CC(=O)O
InChI
1S/C32H55N9O10.C2H4O2/c1-16(2)12-20(38-30(49)26(17(3)4)39-24(44)14-35-23(43)13-33)28(47)40-27(18(5)6)31(50)37-19(9-10-22(34)42)32(51)41-11-7-8-21(41)29(48)36-15-25(45)46;1-2(3)4/h16-21,26-27H,7-15,33H2,1-6H3,(H2,34,42)(H,35,43)(H,36,48)(H,37,50)(H,38,49)(H,39,44)(H,40,47)(H,45,46);1H3,(H,3,4)/t19-,20-,21-,26-,27-;/m0./s1
InChIKey
NYGCNONRVCGHAT-UFIKZEAMSA-N
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) Zonulin Target Info Modulator
References
Ref 522704ClinicalTrials.gov (NCT00925301) Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease. U.S. National Institutes of Health.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.